Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch

niversity Medical Center Utrecht0 个研究点目标入组 325 人开始时间: 2018年1月2日最近更新: 2024年2月27日

适应症

试验速览

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31242931 protocol (added 28/06/2019) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36058230/ (added 05/09/2022) 2019 Abstract results in https://doi.org/10.1177/2396987319848124 (added 13/02/2024) 2021 Abstract results in https://doi.org/10.1177/23969873211044666 (added 13/02/2024) 2022 Abstract results in https://doi.org/10.1177/23969873221087559 (added 13/02/2024)

•1. Age 18 years or older
•2. Probable diagnosis of acute stroke, as assessed by the paramedic in the prehospital setting
•3. Score of 2 or 3 on the Face Arm Speech Test (FAST)
•4. Systolic blood pressure = 140 mm Hg
•5. Possibility to start the trial treatment within 3 hours of symptom onset
•6. Intention to transport the patient to one of the participating hospitals
•7. Written informed consent (deferred)

•1. Considerable pre-stroke dependency in activities of daily living, defined as staying in a chronic nursing home or rehabilitation centre
•2. Known pregnancy or lactation
•3. Indication for acute treatment with nitroglycerin or known use of nitroglycerin in the previous 12 hours
•4. Indication for acute reduction of blood pressure
•5. Known hypersensitivity to GTN, nitrates in general, or the adhesives used in the patch
•6. Glasgow Coma Scale < 8
•7. Known with any of the following heart disorders: myocardial insufficiency due to obstruction; aortic or mitral valve stenosis; constrictive pericarditis; hypertrophic obstructive cardiomyopathy; cardiac tamponade
•8. Known marked anaemia, defined as haemoglobin < 5 mmol/L
•9. Known closed angle glaucoma
•10. Known concomitant use of phosphodiesterase type-5 inhibitors, (e.g. sildenafil, tadalafil, vardenafil)

发起方